Trial · NCT00829179
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
NCT00829179, Phase 3, Completed, Duke University; results first posted 2009-10-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma. Trials, record NCT00829179. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00829179
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
- NCT number
- NCT00829179
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 20 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Allergic Asthma
- Interventions
- RhuMab-E25
- First posted
- 2009-01-26
- Last updated
- 2016-02-08
- Results first posted
- 2009-10-21
- Limitations and caveats
- Pilot study with small sample size.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Exhaled Nitric Oxide From Baseline to Week 12 | 13 weeks | The primary outcome measure was the change in exhaled nitric oxide levels between baseline and week 12. 12 week value minus baseline value. (Baseline was -1 week, ie 1 week prior to the start of study drug) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Exhaled Nitric Oxide From Baseline to Week 12 | 13 weeks | parts per billion (ppb) | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Exhaled Nitric Oxide From Baseline to Week 12 | RhuMab-E25 | -11.0 | Standard Deviation 13.3 | parts per billion (ppb) |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | RhuMab-E25 | 20 | |
| Overall Study | COMPLETED | RhuMab-E25 | 19 | |
| Overall Study | NOT COMPLETED | RhuMab-E25 | 1 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | headache | Nervous system disorders | RhuMab-E25 | 2 | 20 | 3 |
| other | cough | Respiratory, thoracic and mediastinal disorders | RhuMab-E25 | 2 | 20 | 2 |
| other | viral syndrome | Infections and infestations | RhuMab-E25 | 3 | 20 | 3 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | RhuMab-E25 | ||
| Total, other adverse events | RhuMab-E25 | 7 | 20 |
| Total, serious adverse events | RhuMab-E25 | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00829179
GET https://conductscience.org/api/trials/v1/NCT00829179/registered